Doing Everything Right Wasn't Enough

On heart disease, hidden lipid risk, and why sometimes the hardest patients to protect are the ones doing everything correctly.

Some patients arrive with a question. John arrived with a feeling.

And that feeling was growing stronger with time.

He was roughly sixty and looked healthy. He exercised more than most people half his age — still could bench press one and a half times his body weight, and had a VO2max of 40.5, landing him around the 85th percentile for his age group. He hadn’t touched a cigarette in his life. His weight was controlled. His blood pressure, fine. By almost every measure, he was the kind of patient a doctor loves to see walk through the door.

And yet.

“I feel like I’m going to have a heart attack. I just don’t know when.”

He wasn’t catastrophizing. He wasn’t anxious in the clinical sense. He was doing math. And his family history was the equation.

JOHN’S FAMILY HISTORY

Father: Heart attack in early 50s

Mother: Stroke

Brother: Heart attack at age 42

Paternal grandfather: Heart attack in early 50s

Maternal grandfather: Heart attack in 70s

Two paternal uncles: Heart disease

Generations of it. Like a message written in blood, passed down with the last name.

In medicine, we sometimes talk about penetrance — the likelihood that a genetic tendency will actually express itself in a given person. John’s family history didn’t just suggest a predisposition. It was textbook.

What Good Medicine Already Did

Before he came to me, John had a physician. A good one. And what that physician did was exactly right — by every reasonable standard of care.

I want to say something clearly, because it matters: traditional medicine is not broken. If something goes catastrophically wrong — a heart attack, a trauma, an appendix at midnight — you want that system, and you want it fast. The machinery we’ve built to treat acute disease is one of the genuine triumphs of modern science.

His physician started where any good physician would: dietary changes, exercise counseling, and lipid-lowering therapy. The first tools of choice were statins — the cornerstone of cholesterol treatment, among the most studied drugs in medicine. John tried three of them. All three caused myopathy: muscle pain significant enough to interfere with the very exercise that was one of his most powerful cardiovascular tools. So they were stopped.

With statins off the table, his physician kept working. They tried additional medications and supplements. By the time John came to see me, he was on ezetimibe and omega-3s. They also ordered a coronary artery calcium score — twice, four years apart — to monitor whether calcified plaque was building up in his arteries. They were thorough. Methodical.

The problem wasn’t the care. The problem was the container it came in.

With the lifestyle already exceptional, statins exhausted, and other options largely tried, his physician reached a reasonable conclusion: there isn’t much more we can do. But John knew something was still unanswered. And he was right.

The Reassuring Number That Wasn’t

The CAC scan — coronary artery calcium score — is a CT scan that looks for calcified plaque in the arteries of the heart. Think of it as checking whether limestone has built up inside your pipes. Calcium in your coronary arteries signals old, hardened plaque. Scores run from zero upward with no fixed ceiling — mild calcification starts around 1, moderate around 100, and extensive disease can push into the hundreds or thousands. But the number only means something in clinical context. A zero score in a 40-year-old tells you almost nothing; that’s where virtually everyone is. And a low score in a patient with a strong genetic cholesterol disorder may simply mean the plaque burden is predominantly soft and non-calcified — which, as we’ll see, is exactly the kind that doesn’t show up.

John’s score was low and, on repeat four years later, not accelerating. Both times, below average for his age. For good measure, he’d also had a cardiac stress test — not just normal, but remarkable. His cardiorespiratory capacity was outstanding, consistent with everything else we knew about how he lived.

With the CAC scores reassuring, the stress test normal, the statins exhausted, the lifestyle already optimized, and the other interventions tried, there wasn’t an obvious next step. The conclusion made sense given what the tests had shown.

Here is where the case turns.

A low calcium score does not mean your arteries are clean. It means the plaque that’s there hasn’t yet calcified.

And the plaque that kills you — the kind that ruptures, cascades into a clot, causes the sudden catastrophic event — is often soft. Unstable. Lipid-rich. Invisible to calcium scoring. The CAC scan finds the burned logs. It can miss the live flame entirely.

We weren’t finding nothing because there was nothing. We were finding nothing because we were looking in the wrong place.

What Happens When You Have Time to Look

Concierge medicine gets criticized — sometimes fairly — for overtesting and driving costs that most people can’t access. I hold that critique myself every time I consider deviating from practice norms. Every test carries a price, a false positive rate, a potential to pull you somewhere you didn’t need to go.

But John wasn’t a patient with nothing clinically driving the workup. He was a man squarely in the decade when cardiovascular risk accelerates fastest — with a textbook family history for heart disease, documented lipid abnormalities, statin intolerance, a trail of failed interventions, and one unanswered question: am I actually at risk?

In concierge medicine, I have time. Time to stop before I order and ask myself honestly: is this test going to change what I do, or am I just generating data for its own sake? Time to sit with that question. And in John’s case, time to run the kind of extended cardiometabolic panel that the clinical picture genuinely demanded — the kind a 15-minute visit rarely accommodates, not because those physicians aren’t thorough, but because the system they work in wasn’t built for this kind of slow, deliberate detective work.

ApoB — above the 95th percentile.

Your standard cholesterol panel measures LDL-C — roughly how much cholesterol is floating around. ApoB counts the actual particles carrying it. If LDL-C is the total weight of vehicles on a highway, ApoB counts the vehicles. And it matters, because smaller, denser particles — packed with more cholesterol passengers — cross the arterial wall more easily and do more damage. You can have a “normal” LDL-C and still have an alarming number of atherogenic particles quietly depositing themselves inside your arteries. LDL-C misses that. ApoB doesn’t. John’s was above the 95th percentile.

Lp(a) — extremely elevated.

Lipoprotein(a) is a genetically determined, largely unmodifiable cholesterol particle that rarely gets tested for routinely — and is, independently, one of the most potent cardiovascular risk factors we know about. You cannot diet or exercise your way out of a high Lp(a). It’s set at birth, passed down through families the way bone structure is. John’s was sky-high — and almost certainly running through the same branches of that family tree we mapped at the start.

Cholesterol absorption markers — significantly elevated.

Not all cholesterol problems originate in the liver making too much. Some come from the gut absorbing too much. John’s labs pointed directly at this pathway — one that doesn’t respond well to statins but responds directly to ezetimibe, which is exactly what his previous physician had him on. In a way, this was a quiet validation: the right medication had already been chosen, just without the lab evidence to explain why. His liver production markers, meanwhile, were low — an additional clue into why statins may have been a poor fit for his biology to begin with.

Insulin resistance — HOMA-IR nearly 5.

John wasn’t diabetic. He wasn’t even prediabetic by standard fasting glucose thresholds. But his HOMA-IR — a calculated marker of how hard his pancreas was working to keep blood sugar in range — was nearly 5. A healthy number is closer to 1. Insulin resistance doesn’t just precede diabetes. It’s an active driver of vascular inflammation, plaque formation, and endothelial dysfunction. It’s the metabolic equivalent of a slow rust running through your pipes, invisible until the damage is done.

Inflammation — elevated.

Low-grade, smoldering, systemic. The kind that doesn’t make you feel sick. The kind that quietly accelerates everything wrong that’s already happening in your arteries. It was there.

The Phone Call and the Scan

I called a cardiologist I know and trust. Someone I knew would be curious enough to not accept “low calcium score, reassure him” as the final chapter.

We talked through the case. And we agreed: we needed to look beyond calcified plaque. We needed to see the soft stuff.

A coronary CT angiography — a cCTA — is a different kind of window than a calcium score. Where the CAC scan looks for calcification, the cCTA uses contrast dye and high-resolution imaging to visualize the actual walls of the coronary arteries. Every major vessel. Including non-calcified, lipid-rich, soft plaque that a calcium scan would never detect.

Think of it this way. If your coronary arteries are a network of roads, the calcium score shows you where old potholes were filled with gravel. The cCTA shows you the entire road surface — fresh cracks, soft spots, new damage. All of it.

John had his cCTA within a week of his labs returning.

What Nobody Had Seen

His right coronary artery — the RCA, the vessel that feeds the bottom and back of the heart — had a 99% blockage. This blockage was made up of the soft plaque the CAC scan cannot see.

Let that sit for a moment. This is a man who had been exercising intensely and regularly, who had completed a VO2max test in my clinic weeks earlier. His body had been compensating, quietly, for a faucet that was nearly shut.

Not suggestive. Not borderline. Ninety-nine percent.

And it was confirmed to be flow-limiting by the FFR — fractional flow reserve, a measurement that tells us whether a narrowing is severe enough to actually be starving the downstream heart muscle of blood. A positive FFR means yes. John’s was positive.

His left circumflex artery and his left anterior descending artery — the other two major vessels feeding the heart — were diseased as well. Not to the same degree. But diseased.

This man had been living with a nearly closed faucet feeding his heart. Nobody had known it, because the calcium score was low, and the standard labs were telling an incomplete story.

Days later, he underwent cardiac catheterization. His RCA was stented open. The procedure was planned, coordinated, and successful. No heart attack. No ambulance at 2am. No emergency room. Just a stent, placed exactly when and where it was needed.

His follow-up echocardiogram — a measure of how well his heart muscle was actually functioning — was completely normal. The muscle survived. Because it never got the chance to fail.

Where the Story Doesn’t End

Stenting the artery was an intervention. It was not a solution. John almost certainly has heterozygous familial hypercholesterolemia — HeFH, a genetic disorder of cholesterol metabolism that explains much of what we found: the elevated ApoB, the extreme Lp(a), the family history that reads like a warning written across generations.

We got him approved for Nexlizet — a combination of bempedoic acid and ezetimibe, targeting both cholesterol production and gut absorption — and Repatha, a PCSK9 inhibitor, a newer and powerful class of medication that dramatically lowers LDL and ApoB by clearing more cholesterol particles from circulation. His ApoB came down more than 60%. His Lp(a) dropped 50%.

We addressed the insulin resistance directly. His HOMA-IR went from nearly 5 to 1.5. His inflammatory markers normalized completely. The smoldering fire went out.

The Lp(a) remains an ongoing challenge. You can move it, but you cannot yet fully tame it — not with anything we currently have. There are therapies in late-stage clinical trials that may change this, and they represent some of the most exciting developments in preventive cardiology in a decade. We are watching closely. We are waiting.

And we’re sitting with a question the guidelines don’t yet answer: could a repeat cCTA show actual plaque regression after aggressive lipid-lowering? The evidence is still building. But if knowing whether his plaque is stable, shrinking, or progressing might change what we do next — then it’s a question worth asking. In medicine, we don’t order tests that won’t change management. This one might.

What This Is Really About

The conversation online about concierge medicine is usually wrong in both directions. It’s not that one model is good and the other broken. It’s not that concierge physicians know things other doctors don’t. The knowledge is largely the same.

The difference is capacity.

A traditional primary care physician might see 25 patients in a day, 15 minutes each. That system was designed for episodic disease — you come in sick, you leave with a treatment. It’s genuinely excellent at that. But it wasn’t built for someone who is healthy, feels fine, and wants to know what might be quietly developing beneath the surface over the next decade.

In a concierge practice, I can pick up the phone and call a cardiologist on a Tuesday afternoon and actually reach them. I can turn around a PA approval in days because there’s a relationship there, not a fax queue. I can sit with a patient long enough to hear the whole story — not the chief complaint, the whole story.

John deserved an answer to a legitimate clinical question. The answer required more than 15 minutes. That’s all this is.